No Data
Hong Kong stock concept tracking | Medical devices trade-in program attracts institutional attention, clear trend of market recovery.
"Trade-in" is accelerating in the field of medical devices, and various provinces are intensively issuing "feasibility announcements", "project approval announcements" and "tender procurement notices", injecting a dose of "cardiotonic" into the market.
Biomedical stocks are performing strongly. Lai Kai Medicine (02105) rose by 26.26%, institutions pointed out that the sector's valuation has reached a historical low, still with further room for recovery.
Golden Finance News | Biomedical stocks are strong, with LaiKai Pharmaceutical (02105) up 26.26%, AmyMed Vaccine (06660) up 19.76%, YimingAngke (01541) up 7.04%, Hansoh Pharma (03692) up 6.4%, Hutchmed (China) (00013) up 6.91%, Peijia Medical (09996) up 5.75%, Akeso (09926) up 5.77%. Bocom Intl stated that the tenth batch of National Drug Centralized Procurement Volume Document shows the highest historical threshold for this round of national procurement, the highest proportion of injections in history, and expects the competition to be exceptionally fierce, but for
There is no limit on price fluctuation, new stocks are being speculated! The pioneer of ultrasound submits an application for registration on the gem.
Cumulative dividends exceed 0.3 billion in 4 years.
Institutions Profited After Peijia Medical Limited's (HKG:9996) Market Cap Rose HK$484m Last Week but Individual Investors Profited the Most
PEIJIA-B: Interim Report 2024
[Brokerage Focus] Bocom International maintains a "buy" rating on Peijia Medical (09996), pointing out that "outflow restrictions" are the biggest short-term factor suppressing the stock price.
Golden Horse Financial News | BOC International issued research reports, stating that due to adjustments to the Hang Seng Composite SmallCap Index, Piaget Medical (09996) will be removed from the list of stocks eligible for trading via the Hong Kong Stock Connect starting from September 10th. Current market concerns mainly revolve around: 1) Worries on the fundamental side regarding the slowing growth rate of TAVI implants, intensified competition in the TAVI and neurointerventional industries, and central procurement; 2) Concerns on the trading and funding side about the impact on the company's stock price after the "outbound trading" of the Hong Kong Stock Connect. The bank believes that concerns about the fundamentals have been adequately reflected in the previous price corrections, and the main factor suppressing stock prices in the short term is the trading pressure after the "outbound trading". In addition, the bank believes that the market
Peijia Medical Limited's (HKG:9996) 29% Share Price Plunge Could Signal Some RiskNo Data
No Data
